In a randomized placebo-controlled, multicenter phase 1 study, the efficacy and safety of the dual GLP-1/glucagon receptor agonist mazdutide (IBI362) at doses of 9 mg and 10 mg weekly were evaluated in subjects with overweight and obesity. Here, GCGR is linked to Obesity.